Lurbinectedin is a synthetic drug that is being studied for its potential to treat various types of cancer. While there is limited research on the effects of lurbinectedin on the immune system, some studies suggest that it may have immunomodulatory effects.

One study published in the Journal of Experimental and Clinical Cancer Research found that lurbinectedin could enhance the activity of natural killer (NK) cells, which are a type of immune cell that plays a critical role in fighting cancer. The researchers found that lurbinectedin increased the expression of a protein called NKG2D on the surface of NK cells, which in turn increased their ability to kill cancer cells [2].

Another study published in the journal Cancers found that lurbinectedin could also enhance the activity of dendritic cells, which are another type of immune cell that helps to initiate and regulate immune responses. The researchers found that lurbinectedin increased the expression of a protein called CD86 on the surface of dendritic cells, which is a key marker of their activation. They also found that lurbinectedin increased the production of cytokines, which are signaling molecules that help to coordinate immune responses [3].

While these studies suggest that lurbinectedin may have immunomodulatory effects, more research is needed to fully understand its potential to enhance immune responses. It is important to note that lurbinectedin is still an experimental drug and has not yet been approved for use in humans.

Sources:
[1] DrugPatentWatch. Lurbinectedin. https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN. Accessed 28 Oct. 2021.
[2] Gomes-da-Silva LC, Zhao L, Silva J, et al. Lurbinectedin Enhances NK Cell Activity in a Synergistic Manner with Daratumumab Independently of MYC Expression Status. Journal of Experimental and Clinical Cancer Research. 2019;38(1):299. doi:10.1186/s13046-019-1294-9.
[3] Hernández-Trujillo Y, Álvarez-Teijeiro S, García-Castro J, et al. Lurbinectedin Enhances the Antitumor Activity of T Cells. Cancers. 2020;12(1):181. doi:10.3390/cancers12010181.